The management of colorectal liver metastases has advanced remarkably through improvements in systemic chemotherapy and surgical innovation. Conversion surgery has allowed resection in previously unresectable cases, while repeat hepatectomy for recurrence is increasingly recognized as a valuable option. Technical refinements such as parenchymal sparing hepatectomy, two-stage hepatectomy, and ALPPS have also expanded the spectrum of surgical strategies. In selecting among these approaches, however, not only technical considerations but also biological factors-such as tumor aggressiveness and response to systemic therapy-must be carefully taken into account. Differences between Eastern and Western strategies often reflect variations in how surgical indications and oncologic risks are assessed. We also welcome presentations addressing therapeutic approaches. These include genome medicine following whole-genome analysis, molecular targeted therapies at the epigenomic level (including lncRNA and microRNA), activation of tumor immune responses to promote therapies centered on immune checkpoint inhibitors (ICI), and personalized treatment strategies based on liquid biopsy for monitoring minimal residual disease (MRD). We aim to discuss the latest findings that can inform clinical decision-making for liver metastasis treatment. This session will bring together distinguished experts to present the latest evidence, integrating surgical advances with tumor biology, and to foster discussion on refining treatment strategies that can be applied worldwide.